Direxion Daily S&P Biotech Bear 3X ETF
LABD
16 hedge funds and large institutions have $29.9M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 4 closing their positions.
232% more call options, than puts
Call options by funds: $25.3M | Put options by funds: $7.61M
13% more capital invested
Capital invested by funds: $26.5M → $29.9M (+$3.39M)
0.62% more ownership
Funds ownership: 38.35% → 38.98% (+0.62%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
6% less funds holding
Funds holding: 17 → 16 (-1)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.5M |
| 2 |
Jane Street
New York
|
+$2.83M |
| 3 |
Squarepoint
New York
|
+$2.12M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$2M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$4.22M |
| 2 |
HF
HRT Financial
New York
|
-$2.61M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.16M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$966K |
| 5 |
Goldman Sachs
New York
|
-$662K |
LABD Hedge Fund Activity: Q2 2022 in Review
16 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2022, worth a combined $29.9M — up 13% from $26.5M a quarter earlier.
Fund positioning in LABD was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $5.5M. The largest seller was Virtu Financial, exiting entirely with an estimated $4.22M sold.
- 16 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2022, down from 17 in Q1 2022.
- Funds reported $29.9M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2022, up 13% quarter-over-quarter.
- 4 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2022 was Susquehanna International Group, an estimated $5.5M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q2 2022 was Virtu Financial, an estimated $4.22M sold.
Based on aggregated 13F filings for Q2 2022.